Reducing Variability For Apheresis Material For Autologous Cell Therapy

In this segment, our expert panelists address why apheresis material for autologous cell therapy is subject to variability related to its limited quantity (i.e. product yield), the differences between patients (i.e. individual attributes, health status, treatment history), and the differences across apheresis facilities (i.e. equipment, collection processes, freezing techniques).